RITA Rita Medical Systems

Company Achieves Record $12.8 Million Revenue; Expects Key Product Introductions in Second Half of Year FREMONT, Calif., Aug 8 /PRNewswire-FirstCall/ -- RITA Medical Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device company focused solely on cancer therapies, today reported financial results for the second quarter ended June 30, 2006. Highlights -- Achieved record revenue for the third consecutive quarter of $12.8 million. -- Delivered 23% sales growth year to date in Localized Therapy products, which includes radiofrequency ablation, Habib 4X(TM), and LC Beads(TM). -- Second consecutive quarter of specialty access catheter revenue growth. -- Maintained cash position for the first half of 2006 while continuing to make significant investments in new product development programs. -- Acquired exclusive distribution rights to LC Beads in the U.S. and Canada and began shipping product in the second quarter. -- Moved Laparoscopic Habib 4X(TM) resection device introduction from first quarter 2007 to fourth quarter 2006. -- Introduction of Uniblate(TM) RF electrode expected in fourth quarter 2006. Revenue was $12.8 million for the quarter ended June 30, 2006, compared to revenue of $12.5 million in the first quarter of 2006, and compared to revenue of $12.0 million in the second quarter of 2005. The GAAP net loss for the second quarter of 2006 was $1.6 million, or a GAAP net loss per fully diluted share of $0.04, compared with a GAAP net loss in the first quarter of 2006 of $2.0 million or a GAAP net loss per fully diluted share of $0.05. The GAAP net loss for the second quarter of 2005 was $1.4 million or a GAAP net loss per fully diluted share of $0.03. The pro-forma net loss for the second quarter of 2006 was $406,000, or a pro-forma net loss per fully diluted share of $0.01, compared with a pro-forma net loss in the first quarter of 2006 of $891,000 or a pro-forma net loss per fully diluted share of $0.02. The pro-forma net loss excludes FASB 123R stock compensation expense and amortization expense of acquisition intangibles. A reconciliation of the differences between the GAAP net losses and the pro-forma net losses is included in an accompanying table. For the first six months of 2006 revenue was $25.3 million compared with revenue of $23.2 million for the first six months of 2005 for 9.3% year over year growth. The GAAP net loss for the first six months of 2006 was $3.5 million, or a GAAP net loss per fully diluted share of $0.08, compared with a GAAP net loss in the first six months of 2005 of $3.1 million or a GAAP net loss per fully diluted share of $0.07. Cash and cash equivalents were $5.9 million at June 30, 2006, compared with $5.5 million at December 31, 2005. The increase was primarily due to stock option exercises by former employees and positive cash flow from operations for the six month period ended June 30, 2006. "I am very pleased at our results for the quarter and for the first half of the year. Strong sales in our Localized Therapy product platform, which includes RFA, Habib and now LC Beads, is a positive affirmation of our strategy to offer our customers continuum of cancer care solutions for their patients," said Mr. Joseph DeVivo, President and CEO of RITA. "The second half of the year promises to be very exciting as we have several product and clinical milestones we plan to deliver. We are currently planning to introduce a laparoscopic version of our popular Habib 4x resection device ahead of schedule. Early laboratory experiences with several thought leaders have been very positive and we believe that the product will have wide appeal to surgeons." "In the fourth quarter this year we also plan to introduce a single needle RF electrode that offers an adjustable ablation size. The Uniblate(TM) product introduction is planned for the fourth quarter this year and we expect it to add value to our industry-leading RFA product line." "And finally, we plan to have investigational Assure(TM) RF electrodes, which are designed exclusively for radiofrequency-assisted lumpectomy for breast cancer, available for use at two key clinical sites where Investigative Review Board approval for the device has been granted." "We believe that our strategic direction and our continued tactical execution will deliver a successful second half of 2006." Outlook The current outlook ranges for the third quarter ending September 30, 2006 are as follows: -- Revenue -- $12.2 million to $12.7 million -- GAAP net loss -- ($2.1) million to ($2.7) million -- Stock compensation expense included in the GAAP net loss range -- $800,000 to $850,000 -- Pro-forma net loss (excluding stock compensation expense and amortization expense of acquisition intangibles) -- ($950,000) to ($1,500,000) The expected sequential decline in third quarter revenue reflects anticipated normal summer seasonality. The current outlook ranges for the year ending December 31, 2006 are as follows: -- Revenue -- $51.5 million to $53.5 million -- GAAP net loss -- ($5.3) million to ($7.3) million -- Stock compensation expense included in the GAAP net loss range -- $2,800,000 to $3,300,000 -- Pro-forma net loss (excluding stock compensation expense and amortization expense of acquisition intangibles) -- ($1) million to ($2.5) million Additional details pertaining to outlook for the second quarter of 2006 and full year 2006 are included in an accompanying table. Additionally, a reconciliation of the differences between the outlook for the GAAP net losses and the pro-forma net losses are included in an accompanying table. Conference Call today RITA management will host a conference call and webcast today, Tuesday, August 8, 2006, at 2 PM Pacific Time to discuss the Company's second quarter results and its outlook for the remainder of 2006. The dial-in number for the conference call is 800-257-1836 for domestic callers and 303-205-0066 for international callers. A live audio webcast is available at the Company's website http://www.ritamedical.com/ by clicking the "audio webcast" link; no password is required to access the webcast, although webcast participants are encouraged to go to the site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. An audio replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for 7 days. The audio replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers; the passcode for both is 11066571#. An online replay of the audio webcast will be available for one year immediately following the broadcast by accessing the same link. Information regarding the Company's sales by product line and region for the periods ended June 30, 2006 and 2005 is presented in an accompanying table. Any additional financial and other statistical information discussed during the call can be accessed by listening to the audio replay as described above or from the accompanying tables. Use of Non-GAAP Financial Measures The Company uses, and this press release contains and the related conference call will include, the non-GAAP metrics of pro-forma net loss and EBITDA for the periods ended June 30, 2006 and 2005, and pro-forma net loss outlook for the quarter ended September 30, 2006 and year ended December 31, 2006. The calculation of pro-forma net loss and EBITDA (earnings before interest, taxes, depreciation and amortization, and also excluding FASB 123R stock compensation expense, collectively "EBITDA") have no basis in GAAP. The Company believes that all of these non-GAAP financial measures provide useful information to investors, permitting a better evaluation of the Company's ongoing and underlying business performance, including the evaluation of its performance against its competitors in the healthcare industry. A complete reconciliation of these non-GAAP financial measures for historical periods to the most directly comparable GAAP measures is presented in the accompanying tables. Additionally, a reconciliation between the GAAP net loss and the pro- forma net loss for the Company's outlook for the quarter ending September 30, 2006 and the year ending December 31, 2006 is included in an accompanying table. About RITA Medical Systems, Inc. RITA Medical Systems develops, manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems and embolization products for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary Vortex(R) technology; tunneled central venous catheters; and safety infusion sets and peripherally inserted central catheters used primarily in cancer treatment protocols. The radiofrequency product line also includes the HABIB 4X resection device which coagulates a "surgical resection plane" and is designed to facilitate a fast dissection in order to minimize blood loss and blood transfusion during surgery. The proprietary RITA RFA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time for the palliation of pain associated with metastatic lesions involving bone. The Company also distributes LC Bead embolic microspheres in the United States. The LC Bead microspheres are injected into selected vessels to block the blood flow feeding a tumor, causing it to shrink over time, and are often used in combination with radiofrequency ablation (RFA). The RITA Medical Systems website is at http://www.ritamedical.com/ . The statements in this news release related to the use of the Company's technology and the Company's future financial and operating performance, including without limitation the Company's outlook for its financial results for the quarter ending September 30, 2006 and the year ending December 31, 2006; the Company's ability to timely develop, obtain regulatory approval, and introduce new radiofrequency and vascular access products, including the Laparoscopic Habib 4X, Uniblate, and Assure products; physician adoption of the Company's products for treatment of types of cancer other than liver and bone cancers, including breast cancer; the Company's ability to achieve its revenue goals, including its ability to improve revenue growth by selling directly in certain European markets; the Company's ability to market and sell the LC Bead product; the Company's ability to achieve profitability; and the Company's ability to achieve future improvements in operating performance, are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Such risks and uncertainties include but are not limited to: the Company's 2004 material weaknesses in its internal control over financial reporting which were reported in its Annual Report on Form 10K for the year ended December 31, 2004; the timing of product introductions or modifications, including delays caused by technical or regulatory issues; the Company's limited experience selling directly in certain European markets; the Company's limited experience in manufacturing its products in substantial quantities and its reliance on one or two suppliers for several of its products, including Habib 4X; the Company's lack of experience distributing the LC Bead product and its ability to meet its minimum LC Bead purchase requirements; the Company's historical and future operating results and its lack of profitability; market acceptance of the Company's products for existing or new indications; the Company's dependence on international sales; competitive pressures; the ability of users of the Company's products to receive reimbursement from third-party payors, governmental programs or private insurance plans; and general economic and political conditions. Information regarding these and other risks and uncertainties is included in the Company's filings with the Securities and Exchange Commission. RITA MEDICAL SYSTEMS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data, unaudited) Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 Sales $12,800 $11,955 $25,319 $23,160 Cost of goods sold* 4,854 4,623 9,715 9,428 Gross profit 7,946 7,332 15,604 13,732 Operating expenses: Research and development* 1,406 999 2,686 2,038 Selling, general and administrative* 7,808 7,415 16,021 14,183 Restructuring charges -- -- -- 60 Total operating expenses 9,214 8,414 18,707 16,281 Loss from operations (1,268) (1,082) (3,103) (2,549) Interest expense (175) (211) (347) (498) Interest income and (other expense), net (112) (94) (60) (28) Net loss $(1,555) $(1,387) $(3,510) $(3,075) Net loss per common share, basic and diluted $(0.04) $(0.03) $(0.08) $(0.07) Shares used in computing net loss per common share, basic and diluted 43,153 41,548 43,100 41,503 * Figures presented include the following amounts of stock compensation expense: Cost of goods sold $42 $-- $73 $-- Research and development expense 127 -- 212 -- Selling, general and administrative expense 613 34 1,194 34 Total stock compensation expense $782 $34 $1,479 $34 RITA MEDICAL SYSTEMS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, unaudited) June 30, December 31, 2006 2005 Assets Current assets: Cash and cash equivalents $5,881 $5,522 Accounts and note receivable, net 7,658 7,264 Inventories 5,445 5,380 Prepaid assets and other current assets 1,329 941 Total current assets 20,313 19,107 Long term note receivable, net -- 58 Property and equipment, net 1,775 1,959 Goodwill 91,339 91,339 Intangible assets 22,419 23,502 Other assets 432 502 Total assets $136,278 $136,467 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued liabilities $6,265 $5,397 Current portion of long term debt -- 113 Total current liabilities 6,265 5,510 Long term liabilities 9,775 9,762 Stockholders' equity 120,238 121,195 Total liabilities and stockholders' equity $136,278 $136,467 RITA MEDICAL SYSTEMS, INC. SALES BY REGION AND PRODUCT LINE (In thousands, unaudited) Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 Domestic Sales Localized therapy products* $4,779 $3,892 $9,488 $7,493 Specialty Access Catheter Products 5,658 5,846 11,093 11,894 Total 10,437 9,738 20,581 19,387 International Sales Localized therapy products* 1,757 1,270 3,524 2,197 Specialty Access Catheter Products 606 947 1,214 1,576 Total 2,363 2,217 4,738 3,773 Total Sales Localized therapy products* 6,536 5,162 13,012 9,690 Specialty Access Catheter Products 6,264 6,793 12,307 13,470 Total $12,800 $11,955 $25,319 $23,160 * Includes radiofrequency products and embolization products RITA MEDICAL SYSTEMS, INC. PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data, unaudited) Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 Sales $12,800 $11,955 $25,319 $23,160 Cost of goods sold 4,753 4,479 9,524 9,140 Gross profit 8,047 7,476 15,795 14,020 Operating expenses: Research and development 1,279 999 2,474 2,038 Selling, general and administrative 6,887 6,986 14,211 13,358 Restructuring charges -- -- -- 60 Total operating expenses 8,166 7,985 16,685 15,456 Loss from operations (119) (509) (890) (1,436) Interest expense (175) (211) (347) (498) Interest income and (other expense), net (112) (94) (60) (28) Pro-forma Net loss $(406) $(814) $(1,297) $(1,962) Pro-forma Net loss per common share, $(0.01) $(0.02) $(0.03) $(0.05) basic and diluted Shares used in computing net loss per common share, basic and diluted 43,153 41,548 43,100 41,503 Reconciliation of Actual GAAP Net Loss to Non-GAAP Pro Forma Net Loss (in $000) Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 GAAP Net Loss $(1,555) $(1,387) $(3,510) $(3,075) Add: Stock Compensation Cost of Goods 42 -- 73 -- Research and Development 127 -- 212 -- Selling, General and Administrative 613 34 1,194 34 Total Stock Compensation 782 34 1,479 34 Sub-total $(773) $(1,353) $(2,031) $(3,041) Add: Amortization of Acquisition Intangibles Cost of Goods 59 144 118 288 Research and Development -- -- -- -- Selling, General and Administrative 308 395 616 791 Total Amort. Of Acquisition Intangibles 367 539 734 1,079 Non-GAAP Pro Forma Net Loss $(406) $(814) $(1,297) $(1,962) Reconciliation of GAAP Loss to Earnings before Interest, Taxes, Depreciation, Amortization and Stock Compensation Expense (in $000) ("EBITDA") Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 GAAP Net Loss $(1,555) $(1,387) $(3,510) $(3,075) Add: Depreciation 330 242 677 498 Add: Amortization Acquisition Intangibles 367 539 734 1,079 Other Intangibles 175 158 349 332 Add: Interest Expense 175 211 347 498 Deduct: Interest Income (58) (29) (115) (87) Sub-total $(566) $(266) $(1,518) $(755) Add: Stock Compensation Expense 782 34 1,479 34 EBITDA (without Stock compensation expense) $216 $(232) $(39) $(721) Outlook Ranges - Reconciliation of GAAP Net Loss to Non-GAAP Proforma Net Loss (in $000) Three Months Ended Twelve Months Ended September 30, 2006 December 31, 2006 GAAP Net Loss $(2,100) to $(2,700) $(5,300) to $(7,300) Add: Stock Compensation Expense 800 to 850 2,800 to 3,300 Sub-total $(1,300) to $(1,850) $(2,500) to $(4,000) Add: Amortization of Acquisition Intangibles 350 to 350 1,500 to 1,500 Pro-forma Net Loss $(950) to $(1,500) $(1,000) to $(2,500) Outlook Ranges - Additional Details (Dollars in $000) Revenue $12,200 to $12,700 $51,500 to $53,500 Gross Profit Percentage 59.0% to 60.0% 60.0% to 62.0% R&D; SG&A Expenses $8,800 to $8,900 $34,500 to $35,000 (excluding FASB 123R stock compensation expense) Other Expense, primarily interest $200 to $200 $800 to $800 FASB 123R Stock Compensation Expense $800 to $850 $2,800 to $3,300 GAAP Net Loss (including FASB 123R) $(2,100) to $(2,700) $(5,300) to $(7,300) Pro-forma Net Loss $(950) to $(1,500) $(1,000) to $(2,500) (excluding FASB 123R and amortization of acquisition related intangibles) DATASOURCE: RITA Medical Systems, Inc. CONTACT: Joseph DeVivo, President and CEO of RITA Medical Systems, Inc., +1-510-771-0400; or investors, Doug Sherk, , or Jenifer Kirtland, , both at +1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, or , all of EVC Group, for RITA Medical Systems, Inc. Web site: http://www.ritamedical.com/

Copyright